Denovo Taking on Failed Phase III Lilly Drug to Pursue for Genomic Responder Subset

Sep 24, 2014

|

Premium

NEW YORK (GenomeWeb) — Biomarker development firm Denovo Biopharma has acquired the late-stage oncology drug enzastaurin from Eli Lilly and Company, and plans to use its genotyping platform to uncover a genomic marker or markers that can support new clinical trials advancing the drug for a genomic subset of best-responders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Maybe Not to Eat…

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Moving From DC to KC

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Just for Fun?

Slate's Jane Hu compares some at-home genetic tests to astrology.

PLOS Has Skin Cancer Risk Scores and More This Week

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.

Featured White Papers

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

24

Featured Webinar

Comparison of Group B Streptococcus Molecular Assays for Routine Screening in Pregnant Women

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Menu